A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases

Mark Clemons(Ottawa Hospital), Dean Fergusson(Ottawa Hospital), Phillip Blanchette(Western University), Mihaela Mates, Anil A. Joy(University of Alberta), Gregory R. Pond(Juravinski Hospital), John Hilton(Ottawa Hospital), Carol Stober(Ottawa Hospital), O. Aseyev(McMaster University), Angus Robinson(Royal Sussex County Hospital)

Annals of Oncology

May 1, 2019

10.1093/annonc/mdz118.002

Cited by 4

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

|The Lancet|2015|2k

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

|New England Journal of Medicine|2017|1.8k

Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion

|Cochrane Database of Systematic Reviews|2016|1.2k

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.

|PubMed|2007|653

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

|The Lancet Oncology|2019|649